115 results on '"Serfert, Yvonne"'
Search Results
2. Zwischenbilanz
3. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)
4. Hepatitis C – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
5. Interfacial Engineering for the Microencapsulation of Lipophilic Ingredients by Spray-Drying
6. Antimicrobial effect of emulsion-encapsulated isoeugenol against biofilms of food pathogens and spoilage bacteria
7. Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life-data from the German hepatitis C-registry (DHC-R)
8. Enhancing the antibacterial efficacy of isoeugenol by emulsion encapsulation
9. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register)
10. Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry
11. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany
12. Viscosity ratio: A key factor for control of oil drop size distribution in effervescent atomization of oil-in-water emulsions
13. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany
14. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)
15. Declining numbers of hepatitis-C-virus-associated liver transplantations in Germany
16. Process engineering parameters and type of n-octenylsuccinate-derivatised starch affect oxidative stability of microencapsulated long chain polyunsaturated fatty acids
17. Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R)
18. Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern
19. THU-166 - Most vulnerable HCV patient groups treated with direct acting antivirals achieve high response rates and gain quality of life-data from the German hepatitis C-registry (DHC-R)
20. Physicochemical characterization and oxidative stability of fish oil encapsulated in an amorphous matrix containing trehalose
21. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)
22. Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)
23. Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/ pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R)
24. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)
25. Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure : An analysis from the German hepatitis C registry (DHC-R)
26. DHCR_OST-Cannabis_Alcohol_supplementary_2018-10-30_xyz151015746ed84_3-converted – Supplemental material for Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R)
27. Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection-Results from the GermanhHepatitis C-Registry (DHC-R)
28. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany
29. Improvement of Clinical Symptoms and Patient-Reported Outcomes (PRO) after HCV Therapy with Daa in Patients on Opioid Substitution Therapy (OST) - DATA from the German Hepatitis C-Registry (DHC-R)
30. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy : Still a concern in clinical practice?
31. Retreatment with Voxilaprevir/Velpatasvir/Sofosbuvir in Patients with Chronic Hepatitis C Virus Infection and Prior Daa Failure - Results from the German Hepatitis C-Registry (DHC-R)
32. THU-115-Effects of health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection-Results from the GermanhHepatitis C-Registry (DHC-R)
33. THU-188-Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R)
34. Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs)
35. Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten
36. Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen.
37. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
38. THU423 - Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R)
39. THU418 - Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/ pibrentasvir in patients with advanced chronic kidney disease - data from the German hepatitis C-registry (DHC-R)
40. Aktuelle Ergebnisse aus dem Deutschen Hepatitis C-Register
41. Whey protein hydrolysates reduce autoxidation in microencapsulated long chain polyunsaturated fatty acids
42. Comparative Evaluation of Diagnostic Tools for Oxidative Deterioration of Polyunsaturated Fatty Acid-Enriched Infant Formulas during Storage
43. Impact of Physicochemical Characteristics on the Oxidative Stability of Fish Oil Microencapsulated by Spray-Drying
44. Microencapsulation of fish oil withn‐octenylsuccinate‐derivatised starch: Flow properties and oxidative stability
45. Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R).
46. [Significant increase in newly diagnosed hepatitis B and C cases in Germany due to screening].
47. Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany.
48. [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].
49. [Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany].
50. Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.